Interaction Checker

Exemestane interactions

Exemestane (Aromasin), an aromatase inhibitor has 61 documented interactions across the FDA labels and fact sheets we index: 16 major, 33 moderate, 12 minor, and 0 where a label reports no significant interaction. Each entry below quotes the sentence behind it. This drug page is a starting point, not a verdict for your situation.

Interactions from the label

Major interactions (16)

  • Conjugated estrogensestrogenMajor

    Administration with Estrogen-Containing Agents EXEMESTANE should not be coadministered with systemic estrogen-containing agents as these could interfere with its pharmacologic action. (Exemestane label, Warnings and precautions)

  • Conjugated estrogens and bazedoxifeneestrogenMajor

    Administration with Estrogen-Containing Agents EXEMESTANE should not be coadministered with systemic estrogen-containing agents as these could interfere with its pharmacologic action. (Exemestane label, Warnings and precautions)

  • Desogestrel and ethinyl estradioloral contraceptiveMajor

    Administration with Estrogen-Containing Agents EXEMESTANE should not be coadministered with systemic estrogen-containing agents as these could interfere with its pharmacologic action. (Exemestane label, Warnings and precautions)

  • Drospirenone and ethinyl estradioloral contraceptiveMajor

    Administration with Estrogen-Containing Agents EXEMESTANE should not be coadministered with systemic estrogen-containing agents as these could interfere with its pharmacologic action. (Exemestane label, Warnings and precautions)

  • Esterified estrogens and methyltestosteroneestrogenMajor

    Administration with Estrogen-Containing Agents EXEMESTANE should not be coadministered with systemic estrogen-containing agents as these could interfere with its pharmacologic action. (Exemestane label, Warnings and precautions)

  • EstradiolestrogenMajor

    Administration with Estrogen-Containing Agents EXEMESTANE should not be coadministered with systemic estrogen-containing agents as these could interfere with its pharmacologic action. (Exemestane label, Warnings and precautions)

  • Estradiol and dienogestoral contraceptiveMajor

    Administration with Estrogen-Containing Agents EXEMESTANE should not be coadministered with systemic estrogen-containing agents as these could interfere with its pharmacologic action. (Exemestane label, Warnings and precautions)

  • Estradiol and norethindroneestrogenMajor

    Administration with Estrogen-Containing Agents EXEMESTANE should not be coadministered with systemic estrogen-containing agents as these could interfere with its pharmacologic action. (Exemestane label, Warnings and precautions)

  • Ethynodiol diacetate and ethinyl estradioloral contraceptiveMajor

    Administration with Estrogen-Containing Agents EXEMESTANE should not be coadministered with systemic estrogen-containing agents as these could interfere with its pharmacologic action. (Exemestane label, Warnings and precautions)

  • Etonogestrel and ethinyl estradiolestrogenMajor

    Administration with Estrogen-Containing Agents EXEMESTANE should not be coadministered with systemic estrogen-containing agents as these could interfere with its pharmacologic action. (Exemestane label, Warnings and precautions)

  • FulvestrantestrogenMajor

    Administration with Estrogen-Containing Agents EXEMESTANE should not be coadministered with systemic estrogen-containing agents as these could interfere with its pharmacologic action. (Exemestane label, Warnings and precautions)

  • Levonorgestrel and ethinyl estradioloral contraceptiveMajor

    Administration with Estrogen-Containing Agents EXEMESTANE should not be coadministered with systemic estrogen-containing agents as these could interfere with its pharmacologic action. (Exemestane label, Warnings and precautions)

  • Norelgestromin and ethinyl estradiolestrogenMajor

    Administration with Estrogen-Containing Agents EXEMESTANE should not be coadministered with systemic estrogen-containing agents as these could interfere with its pharmacologic action. (Exemestane label, Warnings and precautions)

  • Norethindrone and ethinyl estradioloral contraceptiveMajor

    Administration with Estrogen-Containing Agents EXEMESTANE should not be coadministered with systemic estrogen-containing agents as these could interfere with its pharmacologic action. (Exemestane label, Warnings and precautions)

  • Norgestimate and ethinyl estradioloral contraceptiveMajor

    Administration with Estrogen-Containing Agents EXEMESTANE should not be coadministered with systemic estrogen-containing agents as these could interfere with its pharmacologic action. (Exemestane label, Warnings and precautions)

  • Norgestrel and ethinyl estradioloral contraceptiveMajor

    Administration with Estrogen-Containing Agents EXEMESTANE should not be coadministered with systemic estrogen-containing agents as these could interfere with its pharmacologic action. (Exemestane label, Warnings and precautions)

Moderate interactions (33)

  • AprepitantCYP3A4 inhibitorModerate

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (Exemestane label, Drug interactions)

  • ArmodafinilCNS stimulantModerate

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (Exemestane label, Drug interactions)

  • BosentanCYP3A4 inducerModerate

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (Exemestane label, Drug interactions)

  • CarbamazepineanticonvulsantModerate

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (Exemestane label, Drug interactions)

  • CenobamateanticonvulsantModerate

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (Exemestane label, Drug interactions)

  • ClobazambenzodiazepineModerate

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (Exemestane label, Drug interactions)

  • Deferasiroxiron supplementModerate

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (Exemestane label, Drug interactions)

  • DexamethasonecorticosteroidModerate

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (Exemestane label, Drug interactions)

  • EfavirenzantiretroviralModerate

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (Exemestane label, Drug interactions)

  • Efavirenz, lamivudine, and tenofovirantiretroviralModerate

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (Exemestane label, Drug interactions)

  • EslicarbazepineanticonvulsantModerate

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (Exemestane label, Drug interactions)

  • EtravirineantiretroviralModerate

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (Exemestane label, Drug interactions)

  • FosphenytoinanticonvulsantModerate

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (Exemestane label, Drug interactions)

  • GriseofulvinantifungalModerate

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (Exemestane label, Drug interactions)

  • Lopinavir and ritonavirantiretroviralModerate

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (Exemestane label, Drug interactions)

  • LorlatinibCYP3A4 inducerModerate

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (Exemestane label, Drug interactions)

  • MitapivatCYP3A4 inducerModerate

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (Exemestane label, Drug interactions)

  • MitotaneCYP3A4 inducerModerate

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (Exemestane label, Drug interactions)

  • ModafinilCNS stimulantModerate

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (Exemestane label, Drug interactions)

  • Nafcillinpenicillin antibioticModerate

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (Exemestane label, Drug interactions)

  • NevirapineantiretroviralModerate

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (Exemestane label, Drug interactions)

  • OxcarbazepineanticonvulsantModerate

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (Exemestane label, Drug interactions)

  • PhenobarbitalbarbiturateModerate

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (Exemestane label, Drug interactions)

  • Phentermine and topiramateCNS stimulantModerate

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (Exemestane label, Drug interactions)

  • PhenytoinanticonvulsantModerate

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (Exemestane label, Drug interactions)

  • PrimidoneanticonvulsantModerate

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (Exemestane label, Drug interactions)

  • RifabutinantibioticModerate

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (Exemestane label, Drug interactions)

  • RifampinantibioticModerate

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (Exemestane label, Drug interactions)

  • RifapentineantibioticModerate

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (Exemestane label, Drug interactions)

  • RitonavirantiretroviralModerate

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (Exemestane label, Drug interactions)

  • SuzetrigineCYP3A4 inducerModerate

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (Exemestane label, Drug interactions)

  • Tamoxifenselective estrogen receptor modulatorModerate

    Percent Change in BMD from Baseline to 24 months, Exemestane vs. Control 1 IES 027 BMD Exemestane N=29 Tamoxifen 1 N=38 Exemestane N=59 Placebo 1 N=65 Lumbar spine (%) -3.1 -0.2 -3.5 -2.4 Femoral neck (%) -4.2 -0.3 -4.6 -2.6 During adjuvant treatment with exemestane, women with osteoporosis or at risk of osteoporosis should have their bone mineral density formally… (Exemestane label, Warnings and precautions)

  • TopiramateanticonvulsantModerate

    Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (Exemestane label, Drug interactions)

Minor mentions (12)

  • AlendronatebisphosphonateMinor

    Concomitant use of bisphosphonates, vitamin D supplementation, and calcium was not allowed. (Exemestane label, Warnings and precautions)

  • Calcipotrienevitamin D analogMinor

    • Routine assessment of 25-hydroxy vitamin D levels prior to the start of aromatase inhibitor treatment should be performed ( 5.2 ). (Exemestane label, Warnings and precautions)

  • Calcitriolvitamin D analogMinor

    • Routine assessment of 25-hydroxy vitamin D levels prior to the start of aromatase inhibitor treatment should be performed ( 5.2 ). (Exemestane label, Warnings and precautions)

  • Doxercalciferolvitamin D analogMinor

    • Routine assessment of 25-hydroxy vitamin D levels prior to the start of aromatase inhibitor treatment should be performed ( 5.2 ). (Exemestane label, Warnings and precautions)

  • IbandronatebisphosphonateMinor

    Concomitant use of bisphosphonates, vitamin D supplementation, and calcium was not allowed. (Exemestane label, Warnings and precautions)

  • MegestrolprogestinMinor

    In the comparative study in advanced breast cancer patients, CTC grade 3 or 4 elevation of gamma glutamyl transferase without documented evidence of liver metastasis was reported in 2.7% of patients treated with EXEMESTANE and in 1.8% of patients treated with megestrol acetate. (Exemestane label, Warnings and precautions)

  • PamidronatebisphosphonateMinor

    Concomitant use of bisphosphonates, vitamin D supplementation, and calcium was not allowed. (Exemestane label, Warnings and precautions)

  • Paricalcitolvitamin D analogMinor

    • Routine assessment of 25-hydroxy vitamin D levels prior to the start of aromatase inhibitor treatment should be performed ( 5.2 ). (Exemestane label, Warnings and precautions)

  • Phenobarbital, hyoscyamine, atropine, and scopolaminebarbiturateMinor

    Drugs That Induce CYP 3A4 Co-medications that induce CYP 3A4 (e.g., rifampicin, phenytoin, carbamazepine, phenobarbital, or St. (Exemestane label, Drug interactions)

  • RisedronatebisphosphonateMinor

    Concomitant use of bisphosphonates, vitamin D supplementation, and calcium was not allowed. (Exemestane label, Warnings and precautions)

  • Vitamin DVitamin and mineralMinor

    • Routine assessment of 25-hydroxy vitamin D levels prior to the start of aromatase inhibitor treatment should be performed ( 5.2 ). (Exemestane label, Warnings and precautions)

  • Zoledronic acidbisphosphonateMinor

    Concomitant use of bisphosphonates, vitamin D supplementation, and calcium was not allowed. (Exemestane label, Warnings and precautions)

Check Exemestane against everything you take. Add your full list; every pair is checked at once.

Open in the checker

Not medical advice. Severity reflects the label's wording, not your circumstances. A "major" flag can be routine under supervision and a "minor" one can matter at high doses. Ask a pharmacist.